TY - JOUR
T1 - Levosimendan in Acute and Advanced Heart Failure
T2 - An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications
AU - Altenberger, Johann
AU - Gustafsson, Finn
AU - Harjola, Veli-Pekka
AU - Karason, Kristjan
AU - Kindgen-Milles, Detlef
AU - Kivikko, Matti
AU - Malfatto, Gabriella
AU - Papp, Zoltán
AU - Parissis, John
AU - Pollesello, Piero
AU - Pölzl, Gerhard
AU - Tschöpe, Carsten
PY - 2018/3/1
Y1 - 2018/3/1
N2 - The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data have been collected regarding the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel-opener levosimendan has been proposed as a safer inodilator than traditional agents in some heart failure settings, such as advanced heart failure. At the 2017 annual congress of the Heart Failure Association of the European Society of Cardiology (Paris, April 30-May 2), a series of tutorials delivered by lecturers from 8 European countries examined how to use levosimendan safely and effectively in acute and advanced heart failure. The proceedings of those tutorials have been collated in this review to provide an expert perspective on the optimized use of levosimendan in those settings.
AB - The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data have been collected regarding the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel-opener levosimendan has been proposed as a safer inodilator than traditional agents in some heart failure settings, such as advanced heart failure. At the 2017 annual congress of the Heart Failure Association of the European Society of Cardiology (Paris, April 30-May 2), a series of tutorials delivered by lecturers from 8 European countries examined how to use levosimendan safely and effectively in acute and advanced heart failure. The proceedings of those tutorials have been collated in this review to provide an expert perspective on the optimized use of levosimendan in those settings.
KW - Acute Disease
KW - Cardiotonic Agents/adverse effects
KW - Chronic Disease
KW - Clinical Decision-Making
KW - Congresses as Topic
KW - Databases, Factual
KW - Heart Failure/diagnosis
KW - Humans
KW - Myocardial Contraction/drug effects
KW - Patient Selection
KW - Recovery of Function
KW - Risk Factors
KW - Simendan/adverse effects
KW - Treatment Outcome
KW - Vasodilation/drug effects
KW - Vasodilator Agents/adverse effects
U2 - 10.1097/FJC.0000000000000533
DO - 10.1097/FJC.0000000000000533
M3 - Journal article
C2 - 28817484
SN - 0160-2446
VL - 71
SP - 129
EP - 136
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - 3
ER -